NCT04369183View on ClinicalTrials.gov

Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease

CompletedOBSERVATIONAL
Enrollment

25

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

August 31, 2020

Study Completion Date

October 31, 2020

Conditions
Focal Segmental GlomerulosclerosisMinimal Change Disease
Trial Locations (1)

Unknown

Istanbul University, Istanbul

All Listed Sponsors
lead

Istanbul University

OTHER

NCT04369183 - Rituximab for Refractory or Relapsed Focal Segmental Glomerulosclerosis or Minimal Change Disease | Biotech Hunter | Biotech Hunter